Gastrointestinal and Liver Issues in Heart Failure

Circulation

Volumn 133, Issue 17, 2016, Pages 1696-1703

  Sundaram, Varun ^a   Fang, James C ^b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

gastrointestinal tract; heart failure

Indexed keywords

CARDIOVASCULAR AGENT; CYTOKINE; TUMOR NECROSIS FACTOR ANTIBODY;

ARTICLE; BIOSYNTHESIS; CACHEXIA; CARDIOINTESTINAL SYNDROME; CATABOLISM; CLINICAL TRIAL (TOPIC); DISEASE COURSE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HEART FAILURE; HUMAN; LIVER CIRRHOSIS; LIVER DISEASE; LIVER DYSFUNCTION; LIVER FIBROSIS; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN LOSING GASTROENTEROPATHY; SEVERE HEPATIC IMPAIRMENT; ANIMAL; GASTROINTESTINAL DISEASES; LIVER DISEASES; METABOLISM;

ANIMALS; CARDIOVASCULAR AGENTS; GASTROINTESTINAL DISEASES; HEART FAILURE; HUMANS; LIVER DISEASES;

EID: 84964861235     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.020894     Document Type: Article

References (83)

1. Braunwald E. Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia, PA: WB Saunders; 2015.
2. Mann DL. Mechanisms and models in heart failure: a combinatorial approach. Circulation. 1999;100:999-1008.
3. Braunwald E, Bristow MR. Congestive heart failure: fifty years of progress. Circulation. 2000;102(suppl 4):IV14-IV23.
4. Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet. 2000;356:930-933. doi: 10.1016/S0140-6736(00)02690-8.
5. Sandek A, Rauchhaus M, Anker SD, von Haehling S. The emerging role of the gut in chronic heart failure. Curr Opin Clin Nutr Metab Care. 2008;11:632-639. doi: 10.1097/MCO.0b013e32830a4c6e.
6. Yndestad A, Damås JK, Oie E, Ueland T, Gullestad L, Aukrust P. Systemic inflammation in heart failure: the whys and wherefores. Heart Fail Rev. 2006;11:83-92. doi: 10.1007/s10741-006-9196-2.
7. Anker SD, Coats AJ. Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation. Chest. 1999;115:836-847.
8. Anker SD, Sharma R. The syndrome of cardiac cachexia. Int J Cardiol. 2002;85:51-66.
9. Bourge RC, Abraham WT, Adamson PB, Aaron MF, Aranda JM Jr, Magalski A, Zile MR, Smith AL, Smart FW, O'Shaughnessy MA, Jessup ML, Sparks B, Naftel DL, Stevenson LW; COMPASS-HF Study Group. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. J Am Coll Cardiol. 2008;51:1073-1079. doi: 10.1016/j.jacc.2007.10.061.
10. Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, Strickland W, Neelagaru S, Raval N, Krueger S, Weiner S, Shavelle D, Jeffries B, Yadav JS; CHAMPION Trial Study Group. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377:658-666. doi: 10.1016/S0140-6736(11)60101-3.
11. Ritzema J, Troughton R, Melton I, Crozier I, Doughty R, Krum H, Walton A, Adamson P, Kar S, Shah PK, Richards M, Eigler NL, Whiting JS, Haas GJ, Heywood JT, Frampton CM, Abraham WT; Hemodynamically Guided Home Self-Therapy in Severe Heart Failure Patients (HOMEOSTASIS) Study Group. Physician-directed patient self-management of left atrial pressure in advanced chronic heart failure. Circulation. 2010;121:1086-1095. doi: 10.1161/CIRCULATIONAHA.108.800490.
12. Gelman S. Venous function and central venous pressure: a physiologic story. Anesthesiology. 2008;108:735-748. doi: 10.1097/ALN.0b013e3181672607.
13. Fallick C, Sobotka PA, Dunlap ME. Sympathetically mediated changes in capacitance redistribution of the venous reservoir as a cause of decompensation. Circ Heart Fail. 2011;4:669-675. doi: 10.1161/CIRCHEARTFAILURE.111.961789.
14. Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart. 2004;90:464-470.
15. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323:236-241. doi: 10.1056/NEJM199007263230405.
16. Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, Niebauer J, Hooper J, Volk HD, Coats AJ, Anker SD. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation. 2000;102:3060-3067.
17. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res. 2002;91:988-998.
18. Brandtzaeg P, Halstensen TS, Kett K, Krajci P, Kvale D, Rognum TO, Scott H, Sollid LM. Immunobiology and immunopathology of human gut mucosa: humoral immunity and intraepithelial lymphocytes. Gastroenterology. 1989;97:1562-1584.
19. Salminen S, Bouley C, Boutron-Ruault MC, Cummings JH, Franck A, Gibson GR, Isolauri E, Moreau MC, Roberfroid M, Rowland I. Functional food science and gastrointestinal physiology and function. Br J Nutr. 1998;80(suppl 1):S147-S171.
20. Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, Poole-Wilson PA, Coats AJ, Anker SD. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet. 1999;353:1838-1842. doi: 10.1016/S0140-6736(98)09286-1.
21. Krack A, Sharma R, Figulla HR, Anker SD. The importance of the gastrointestinal system in the pathogenesis of heart failure. Eur Heart J. 2005;26:2368-2374. doi: 10.1093/eurheartj/ehi389.
22. Sandek A, Bauditz J, Swidsinski A, Buhner S, Weber-Eibel J, von Haehling S, Schroedl W, Karhausen T, Doehner W, Rauchhaus M, Poole-Wilson P, Volk HD, Lochs H, Anker SD. Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol. 2007;50:1561-1569. doi: 10.1016/j.jacc.2007.07.016.
23. Tang WH, Wang Z, Fan Y, Levison B, Hazen JE, Donahue LM, Wu Y, Hazen SL. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. J Am Coll Cardiol. 2014;64:1908-1914. doi: 10.1016/j.jacc.2014.02.617.
24. Krack A, Richartz BM, Gastmann A, Greim K, Lotze U, Anker SD, Figulla HR. Studies on intragastric PCO2 at rest and during exercise as a marker of intestinal perfusion in patients with chronic heart failure. Eur J Heart Fail. 2004;6:403-407. doi: 10.1016/j.ejheart.2004.03.002.
25. Costanza AC, Moscavitch SD, Faria Neto HC, Mesquita ET. Probiotic therapy with Saccharomyces boulardii for heart failure patients: a randomized, double-blind, placebo-controlled pilot trial. Int J Cardiol. 2015;179:348-350. doi: 10.1016/j.ijcard.2014.11.034.
26. Anker SD, Rauchhaus M. Insights into the pathogenesis of chronic heart failure: immune activation and cachexia. Curr Opin Cardiol. 1999;14:211-216.
27. von Haehling S, Doehner W, Anker SD. Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc Res. 2007;73:298-309. doi: 10.1016/j.cardiores.2006.08.018.
28. Anker SD, Coats AJ. Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation. Chest. 1999;115:836-847.
29. Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ, Poole-Wilson PA, Coats AJ. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 1997;96:526-534.
30. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656-660. doi: 10.1038/45230.
31. Castellano G, Affuso F, Di Conza P, Fazio S. The GH/IGF-1 axis and heart failure. Curr Cardiol Rev. 2009;5:203-215.
32. Nagaya N, Uematsu M, Kojima M, Date Y, Nakazato M, Okumura H, Hosoda H, Shimizu W, Yamagishi M, Oya H, Koh H, Yutani C, Kangawa K. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation. 2001;104:2034-2038.
33. Nagaya N, Uematsu M, Kojima M, Ikeda Y, Yoshihara F, Shimizu W, Hosoda H, Hirota Y, Ishida H, Mori H, Kangawa K. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation. 2001;104:1430-1435.
34. Bozkurt B, Torre-Amione G, Warren MS, Whitmore J, Soran OZ, Feldman AM, Mann DL. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation. 2001;103:1044-1047.
35. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT; Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107:3133-3140. doi: 10.1161/01.CIR.0000077913.60364.D2.
36. Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, Mann DL. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 1996;93:704-711.
37. Krown KA, Page MT, Nguyen C, Zechner D, Gutierrez V, Comstock KL, Glembotski CC, Quintana PJ, Sabbadini RA. Tumor necrosis factor alphainduced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest. 1996;98:2854-2865. doi: 10.1172/JCI119114.
38. Horwich TB, Kalantar-Zadeh K, MacLellan RW, Fonarow GC. Albumin levels predict survival in patients with systolic heart failure. Am Heart J. 2008;155:883-889. doi: 10.1016/j.ahj.2007.11.043.
39. Chan FK, Sung JJ, Ma KM, Leung YL, Yeung VT. Protein-losing enteropathy in congestive heart failure: diagnosis by means of a simple method. Hepatogastroenterology. 1999;46:1816-1818.
40. Rychik J. Protein-losing enteropathy after Fontan operation. Congenit Heart Dis. 2007;2:288-300. doi: 10.1111/j.1747-0803.2007.00116.x.
41. Arques S, Ambrosi P. Human serum albumin in the clinical syndrome of heart failure. J Card Fail. 2011;17:451-458. doi: 10.1016/j. cardfail.2011.02.010.
42. Doungngern T, Huckleberry Y, Bloom JW, Erstad B. Effect of albumin on diuretic response to furosemide in patients with hypoalbuminemia. Am J Crit Care. 2012;21:280-286. doi: 10.4037/ajcc2012999.
43. Biancone L, Fantini M, Tosti C, Bozzi R, Vavassori P, Pallone F. Fecal alpha 1-antitrypsin clearance as a marker of clinical relapse in patients with Crohn's disease of the distal ileum. Eur J Gastroenterol Hepatol. 2003;15:261-266. doi: 10.1097/01.meg.0000049990.68425.c8.
44. Becker K, Berger M, Niederau C, Frieling T. Individual fecal alpha 1-antitrypsin excretion reflects clinical activity in Crohn's disease but not in ulcerative colitis. Hepatogastroenterology. 1999;46:2309-2314.
45. Wang SJ, Tsai SC, Lan JL. Tc-99m albumin scintigraphy to monitor the effect of treatment in protein-losing gastroenteropathy. Clin Nucl Med. 2000;25:197-199.
46. Davidson JD, Waldmann TA, Goodman DS, Gordon RS Jr. Protein-losing gastroenteropathy in congestive heart-failure. Lancet. 1961;1:899-902.
47. Rueda Soriano J, Zorio Grima E, Arnau Vives MA, Osa Sáez A, Martínez Dolz L, Almenar Bonet L, Palencia Pérez MA, Salvador Sanz A. Reversal of protein-losing enteropathy after heart transplantation in young patients. Rev Esp Cardiol. 2009;62:937-940.
48. Ogawa R, Stachnik JM, Echizen H. Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally). Clin Pharmacokinet. 2014;53:1083-1114. doi: 10.1007/s40262-014-0189-3.
49. Arutyunov GP, Kostyukevich OI, Serov RA, Rylova NV, Bylova NA. Collagen accumulation and dysfunctional mucosal barrier of the small intestine in patients with chronic heart failure. Int J Cardiol. 2008;125:240-245. doi: 10.1016/j.ijcard.2007.11.103.
50. Zordoky BN, El-Kadi AO. Modulation of cardiac and hepatic cytochrome P450 enzymes during heart failure. Curr Drug Metab. 2008;9:122-128.
51. Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther. 2009;85:434-438. doi: 10.1038/clpt.2008.302.
52. Kostis JB. Differences among ACE inhibitors. Am J Hypertens. 2010;23:1156. doi: 10.1038/ajh.2010.170.
53. Vasko MR, Cartwright DB, Knochel JP, Nixon JV, Brater DC. Furosemide absorption altered in decompensated congestive heart failure. Ann Intern Med. 1985;102:314-318.
54. Brater DC. Clinical pharmacology of loop diuretics in health and disease. Eur Heart J. 1992;13 Suppl G:10-14.
55. Sherlock S. The liver in heart failure; relation of anatomical, functional, and circulatory changes. Br Heart J. 1951;13:273-293.
56. Safran AP, Schaffner F. Chronic passive congestion of the liver in man: electron microscopic study of cell atrophy and intralobular fibrosis. Am J Pathol. 1967;50:447-463.
57. Runyon BA. Cardiac ascites: a characterization. J Clin Gastroenterol. 1988;10:410-412.
58. Wanless IR, Liu JJ, Butany J. Role of thrombosis in the pathogenesis of congestive hepatic fibrosis (cardiac cirrhosis). Hepatology. 1995;21:1232-1237.
59. van Deursen VM, Damman K, Hillege HL, van Beek AP, van Veldhuisen DJ, Voors AA. Abnormal liver function in relation to hemodynamic profile in heart failure patients. J Card Fail. 2010;16:84-90. doi: 10.1016/j. cardfail.2009.08.002.
60. Melenovsky V, Hwang SJ, Lin G, Redfield MM, Borlaug BA. Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J. 2014;35:3452-3462. doi: 10.1093/eurheartj/ehu193.
61. Zardi EM, Abbate A, Zardi DM, Dobrina A, Margiotta D, Van Tassell BW, Van Tassel BW, Afeltra A, Sanyal AJ. Cirrhotic cardiomyopathy. J Am Coll Cardiol. 2010;56:539-549. doi: 10.1016/j.jacc.2009.12.075.
62. Richman SM, Delman AJ, Grob D. Alterations in indices of liver function in congestive heart failure with particular reference to serum enzymes. Am J Med. 1961;30:211-225.
63. Allen LA, Felker GM, Pocock S, McMurray JJ, Pfeffer MA, Swedberg K, Wang D, Yusuf S, Michelson EL, Granger CB; CHARM Investigators. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail. 2009;11:170-177. doi: 10.1093/eurjhf/hfn031.
64. Giallourakis CC, Rosenberg PM, Friedman LS. The liver in heart failure. Clin Liver Dis. 2002;6:947-67, viii.
65. Seeto RK, Fenn B, Rockey DC. Ischemic hepatitis: clinical presentation and pathogenesis. Am J Med. 2000;109:109-113.
66. Henrion J, Descamps O, Luwaert R, Schapira M, Parfonry A, Heller F. Hypoxic hepatitis in patients with cardiac failure: incidence in a coronary care unit and measurement of hepatic blood flow. J Hepatol. 1994;21:696-703.
67. Gitlin N, Serio KM. Ischemic hepatitis: widening horizons. Am J Gastroenterol. 1992;87:831-836.
68. Cohen JA, Kaplan MM. Left-sided heart failure presenting as hepatitis. Gastroenterology. 1978;74:583-587.
69. Klemperer JD, Ko W, Krieger KH, Connolly M, Rosengart TK, Altorki NK, Lang S, Isom OW. Cardiac operations in patients with cirrhosis. Ann Thorac Surg. 1998;65:85-87.
70. Bizouarn P, Ausseur A, Desseigne P, Le Teurnier Y, Nougarede B, Train M, Michaud JL. Early and late outcome after elective cardiac surgery in patients with cirrhosis. Ann Thorac Surg. 1999;67:1334-1338.
71. Gelow JM, Desai AS, Hochberg CP, Glickman JN, Givertz MM, Fang JC. Clinical predictors of hepatic fibrosis in chronic advanced heart failure. Circ Heart Fail. 2010;3:59-64. doi: 10.1161/CIRCHEARTFAILURE.109.872556.
72. Bosch J, Mastai R, Kravetz D, Navasa M, Rodés J. Hemodynamic evaluation of the patient with portal hypertension. Semin Liver Dis. 1986;6:309-317. doi: 10.1055/s-2008-1040613.
73. Reynolds TB, Ito S, Iwatsuki S. Measurement of portal pressure and its clinical application. Am J Med. 1970;49:649-657.
74. Suk KT, Kim HC, Namkung S, Han SH, Choi KC, Park SH, Sung HT, Kim CH, Kim SH, Ham YL, Kang HM, Kim DJ. Diagnostic accuracy of hepatic venous pressure gradient measurement in the prediction of stage 1 compensated liver cirrhosis in patients with chronic hepatitis B. Eur J Gastroenterol Hepatol. 2013;10:1170-1176.
75. Myers RP, Cerini R, Sayegh R, Moreau R, Degott C, Lebrec D. Cardiac hepatopathy: clinical, hemodynamic, and histologic characteristics and correlations. Hepatology. 2003;37:393-400.
76. Kim MS, Kato TS, Farr M, Wu C, Givens RC, Collado E, Mancini DM, Schulze PC. Hepatic dysfunction in ambulatory patients with heart failure: application of the MELD scoring system for outcome prediction. J Am Coll Cardiol. 2013;61:2253-2261. doi: 10.1016/j.jacc.2012.12.056.
77. Russell SD, Rogers JG, Milano CA, Dyke DB, Pagani FD, Aranda JM, Klodell CT Jr, Boyle AJ, John R, Chen L, Massey HT, Farrar DJ, Conte JV; Heart Mate II Clinical Investigators. Renal and hepatic function improve in advanced heart failure patients during continuous-flow support with the Heart Mate II left ventricular assist device. Circulation. 2009;120:2352-2357. doi: 10.1161/CIRCULATIONAHA.108.814863.
78. Dichtl W, Vogel W, Dunst KM, Grander W, Alber HF, Frick M, Antretter H, Laufer G, Pachinger O, Pölzl G. Cardiac hepatopathy before and after heart transplantation. Transpl Int. 2005;18:697-702. doi: 10.1111/j.1432-2277.2005.00122.x.
79. Johnsson G, Regàrdh CG. Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs. Clin Pharmacokinet. 1976;1:233-263.
80. Opie L, Gersh B. Drugs for the Heart. 8th ed. New York, NY: Elsevier; 2013.
81. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation. 1998;97:1411-1420.
82. Sungaila I, Bartle WR, Walker SE, De Angelis C, Uetrecht J, Pappas C, Vidins E. Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites. Gastroenterology. 1992;102:1680-1685.
83. Deedwani P. Selective and specific inhibition of If with ivabradine for the treatment of coronary artery disease or heart failure. Drugs. 2013;73:1569-1586.